Open an account

Oruka Therapeutics

ORKA · NASDAQ

$79.09+$4.61 (+6.19%)TodayMarket closed ·
Prev close $74.48

ORKA analyst rating

BuyConsensus of 10 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy10
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 15 analysts

Average $156.22 (+97.5% upside)

Low
$118.17
Now
$79.09
High
$210.00

Upgrades and downgrades

The latest rating actions, newest first

ORKA analyst upgrades, downgrades and rating actions
FirmDateActionRating
BTIGOct 19, 2026MaintainsBuy
WedbushSep 24, 2026MaintainsOutperform
HC Wainwright & Co.Sep 24, 2026MaintainsBuy
HC Wainwright & Co.Sep 3, 2026MaintainsBuy
GuggenheimAug 11, 2026MaintainsBuy
WedbushAug 11, 2026MaintainsOutperform
BTIGAug 11, 2026MaintainsBuy
HC Wainwright & Co.Aug 3, 2026MaintainsBuy
BTIGJul 13, 2026MaintainsBuy
UBSJul 1, 2026MaintainsBuy

The case for and against

Updated Oct 14, 2026

Bull case

Oruka Therapeutics is viewed favorably because ORKA-001 has shown unusually strong psoriasis efficacy, with PASI 100 rising to 71.4% at Week 28 and no re-dosing, while safety remained clean with no injection-site reactions and unrelated serious adverse events. Its competitive appeal is reinforced by infrequent maintenance dosing versus marketed biologics and by a sizable $1.1B cash, cash equivalents and marketable securities position at the midpoint of 2026, which supports development through the anticipated BLA filing for ORKA-001 and continued work on ORKA-002. The outlook is further strengthened by ORKA-004 expanding the pipeline and by the addition of seasoned commercial leadership, both of which improve the chance of successful execution and strategic optionality.

Bear case

Oruka Therapeutics is a clinical-stage company with a highly speculative valuation, as its thesis depends on ORKA-001 and ORKA-002 reaching pivotal trials, proving compelling efficacy, and ultimately securing approvals despite only a 75% and 40% modeled probability of approval, respectively. The business also faces meaningful financing and dilution risk because it will need access to capital markets to fund development and commercialization, while a 2Q26 net loss of $0.55 per share and projected full-year 2026 and 2027 losses of $2.54 and $2.82 per share underscore ongoing cash burn. Its biologic pipeline may have attractive peak sales estimates of ~$2.8B for ORKA-001 and ~$2.5B for ORKA-002, but broad I&I competition, regulatory uncertainty, and the possibility of slower uptake make the execution risk especially high.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.